In Silico Tools in Predictive Toxicology at Merck KGaA- An Interview with Philip Hewitt
Pharma IQ:What are the major challenges that we face in predictive toxicology?Phil Hewitt: The biggest challenge is acceptance from management. I'm talking from experience at Merck, not globally. Because the assays you're developing to predict a human outcome haven't been proven, in most cases, relying on weak or spurious data from other people makes it challenging. Also, the predictivity of most of these early assays is pretty poor for certain toxicological o...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.